VelosBio


Research-intensive biopharmaceutical company focused on discovery, development, manufacturing and distribution of medicines, vaccines, biologic therapies and animal-health products, with capabilities spanning clinical development, large-scale manufacturing, regulatory compliance, partnerships and targeted investments to expand access to health.

Industries

biotechnology
health-care
medical
oncology

Nr. of Employees

small (1-50)

VelosBio

San Diego, California, United States, North America


Patents

Anti-ROR1 / anti-CD3 bispecific binding molecules

US-12655217-B2

View Details

Anti-ROR1 antibodies and compositions

US-12497454-B2

View Details

Products

Veterinary pharmaceuticals, vaccines and animal-health solutions

A portfolio of veterinary therapeutics, vaccines and connected animal-health technologies for identification, traceability and monitoring.


Services

Venture and impact investments into funds and companies addressing health-system infrastructure, diagnostics, digital health and other innovations to improve access to care.

Management and distribution of donated medicines and vaccines through qualified NGO partners for humanitarian response and ongoing programs in low- and middle-income countries.

Financial grants and community partnerships aimed at reducing health disparities, strengthening local health systems and supporting public-health initiatives.

Expertise Areas

  • Clinical trial management and transparency
  • Vaccine and biologic discovery & manufacturing
  • Oncology research (including immuno-oncology and precision targeting)
  • Immunology and target discovery
  • Show More (11)

Key Technologies

  • Artificial intelligence and data-science analytics
  • Real-world evidence analytics
  • Next-generation vaccine and biologics production platforms
  • Clinical trial registries and data-sharing platforms
  • Show More (6)

News & Updates

Corporate impact and sustainability report outlining access-to-health, environmental and social metrics and updated goals.

Announcement and summary of measurable progress and updated 2030 goals related to sustainability and access to health.

Reported reach of more than 400 million people with medicines and vaccines in 2025.

Reported achievement of 100% renewable energy goal for operations in 2025.

Impact Venture Fund received external recognitions, including innovation awards.

Reported R&D investment of $15.8 billion and a large research workforce supporting pipeline activities.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.